Company description

Vanda Pharmaceuticals Inc. (VNDA) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for central nervous system disorders. The company was founded in 2003 and is headquartered in Washington D.C. VNDA's primary product, Hetlioz, is an FDA-approved treatment for Non-24-Hour Sleep-Wake Disorder, a rare sleep disorder affecting blind individuals. Hetlioz is the first and only FDA-approved treatment for this condition, and the company holds exclusive global rights to it. In addition to Hetlioz, VNDA has a robust pipeline of other therapeutic products in different stages of development for different CNS disorders, including schizophrenia, migraines, and jet lag disorder. The company utilizes a proprietary platform called TASL (Tetra Antisense Locked Nucleic Acid) to develop these new treatments. Vanda also has a strong presence in international markets, with Hetlioz being approved for commercialization in Europe, Australia, and Japan. The company has partnerships and collaborations with other pharmaceutical companies to expand its global reach and enhance its research and development capabilities. Furthermore, VNDA prides itself on its commitment to innovation and patient-centricity, striving to improve the lives of those living with challenging CNS disorders. The company has received numerous accolades and awards for its groundbreaking work, solidifying its position as a leader in the biopharmaceutical industry. Overall, Vanda Pharmaceuticals Inc. (VNDA) continues to show promising